Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Short-term Investments (2021 - 2023)

Historic Short-term Investments for HCW Biologics (HCWB) over the last 3 years, with Q2 2023 value amounting to $10.0 million.

  • HCW Biologics' Short-term Investments fell 4139.31% to $10.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $10.0 million, marking a year-over-year decrease of 4139.31%. This contributed to the annual value of $9.7 million for FY2022, which is 6103.06% down from last year.
  • As of Q2 2023, HCW Biologics' Short-term Investments stood at $10.0 million, which was down 4139.31% from $9.8 million recorded in Q1 2023.
  • Over the past 5 years, HCW Biologics' Short-term Investments peaked at $25.0 million during Q3 2021, and registered a low of $9.7 million during Q4 2022.
  • Its 3-year average for Short-term Investments is $16.2 million, with a median of $17.0 million in 2022.
  • Per our database at Business Quant, HCW Biologics' Short-term Investments tumbled by 6103.06% in 2022 and then tumbled by 4139.31% in 2023.
  • HCW Biologics' Short-term Investments (Quarter) stood at $25.0 million in 2021, then crashed by 61.03% to $9.7 million in 2022, then grew by 2.3% to $10.0 million in 2023.
  • Its Short-term Investments stands at $10.0 million for Q2 2023, versus $9.8 million for Q1 2023 and $9.7 million for Q4 2022.